HRA Pharma Development

HRA Pharma is a specialty pharmaceutical company focused on women's health and rare diseases, headquartered in France. The company is a global leader in emergency contraception, having developed and commercialized the ulipristal acetate-based product EllaOne. In addition to its reproductive health portfolio, HRA Pharma maintains a dedicated rare disease division that provides treatments for endocrine conditions such as Cushing's syndrome and adrenocortical carcinoma. Following its acquisition by Perrigo in 2022, the company achieved a significant milestone by launching Opill, the first daily oral contraceptive available over-the-counter in the United States. HRA Pharma continues to operate as a key innovation hub within Perrigo's consumer self-care portfolio.